Jon Congleton

CIK: 0001644975

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)22 (78.6%)

Position reduction

Option Exercises (M)1 (3.6%)

Derivative conversions

Awards (A)5 (17.9%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

MLYS

Mineralys Therapeutics, Inc.

DirectorOfficer

IMUX

IMMUNIC, INC.

Director

AVLN

Avalyn Pharma Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (28 total)

MLYS
Mineralys Therapeutics, Inc.
Sep 30, 2026
Sale(S)
Direct
75K shares at avg. $25.46$1.9M
MLYS
Mineralys Therapeutics, Inc.
Jul 13, 2026
Sale(S)
Direct
10.7K shares at avg. $27.24$291K
IMUX
IMMUNIC, INC.
Jul 5, 2026
Award(A)
Stock Option
Direct
25.4K shares-
MLYS
Mineralys Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
17K shares at avg. $26.82$456K
MLYS
Mineralys Therapeutics, Inc.
Jun 30, 2026
Sale(S)
Direct
58K shares at avg. $25.94$1.5M
IMUX
IMMUNIC, INC.
Jun 29, 2026
Award(A)
Stock Option
Direct
50.7K shares-
AVLN
Avalyn Pharma Inc.
Apr 29, 2026
Award(A)
Stock Option (Right to Buy)
Direct
27K shares-
MLYS
Mineralys Therapeutics, Inc.
Apr 13, 2026
Sale(S)
Direct
15.7K shares at avg. $26.83$422K
MLYS
Mineralys Therapeutics, Inc.
Mar 31, 2026
Sale(S)
Direct
19.4K shares at avg. $25.50$494K
MLYS
Mineralys Therapeutics, Inc.
Mar 31, 2026
Sale(S)
Direct
55.2K shares at avg. $26.54$1.5M
MLYS
Mineralys Therapeutics, Inc.
Mar 31, 2026
Sale(S)
Direct
453 shares at avg. $27.05$12K
MLYS
Mineralys Therapeutics, Inc.
Feb 19, 2026
Award(A)
Direct
140.9K shares-
MLYS
Mineralys Therapeutics, Inc.
Jan 12, 2026
Sale(S)
Direct
9.1K shares at avg. $32.21$294K
MLYS
Mineralys Therapeutics, Inc.
Jan 12, 2026
Sale(S)
Direct
7.1K shares at avg. $33.15$236K
MLYS
Mineralys Therapeutics, Inc.
Nov 21, 2025
Exercise(M)
Direct
24.1K shares at avg. $0.54$13K
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
32.9K shares at avg. $46.89$1.5M
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
112.3K shares at avg. $45.83$5.1M
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
29.2K shares at avg. $45.20$1.3M
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
4K shares at avg. $43.50$174K
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
8.9K shares at avg. $42.31$375K
MLYS
Mineralys Therapeutics, Inc.
Nov 11, 2025
Sale(S)
Direct
12.8K shares at avg. $41.64$533K
MLYS
Mineralys Therapeutics, Inc.
Oct 13, 2025
Sale(S)
Direct
13.5K shares at avg. $42.63$578K
MLYS
Mineralys Therapeutics, Inc.
Oct 13, 2025
Sale(S)
Direct
1.6K shares at avg. $43.03$67K
MLYS
Mineralys Therapeutics, Inc.
Jul 11, 2025
Sale(S)
Direct
15.9K shares at avg. $14.51$230K
MLYS
Mineralys Therapeutics, Inc.
Apr 11, 2025
Sale(S)
Direct
15.3K shares at avg. $12.19$187K

		Type	Shares	Price		Ownership
Sep 30, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	75,000	$25.46	$1,909,665	Direct
Jul 13, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	10,700	$27.24	$291,441	Direct
Jul 5, 2026	IMUX IMMUNIC, INC.	Award(A) Stock Option	25,370	-	-	Direct
Jun 30, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	17,000	$26.82	$455,896	Direct
Jun 30, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	58,000	$25.94	$1,504,706	Direct
Jun 29, 2026	IMUX IMMUNIC, INC.	Award(A) Stock Option	50,740	-	-	Direct
Apr 29, 2026	AVLN Avalyn Pharma Inc.	Award(A) Stock Option (Right to Buy)	26,978	-	-	Direct
Apr 13, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	15,730	$26.83	$421,979	Direct
Mar 31, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	19,364	$25.50	$493,794	Direct
Mar 31, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	55,183	$26.54	$1,464,474	Direct
Mar 31, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	453	$27.05	$12,254	Direct
Feb 19, 2026	MLYS Mineralys Therapeutics, Inc.	Award(A)	140,900	-	$0	Direct
Jan 12, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	9,119	$32.21	$293,707	Direct
Jan 12, 2026	MLYS Mineralys Therapeutics, Inc.	Sale(S)	7,117	$33.15	$235,932	Direct
Nov 21, 2025	MLYS Mineralys Therapeutics, Inc.	Exercise(M)	24,082	$0.54	$13,004	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	32,850	$46.89	$1,540,212	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	112,275	$45.83	$5,145,956	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	29,207	$45.20	$1,320,165	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	4,000	$43.50	$173,984	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	8,862	$42.31	$374,947	Direct
Nov 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	12,806	$41.64	$533,235	Direct
Oct 13, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	13,548	$42.63	$577,544	Direct
Oct 13, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	1,552	$43.03	$66,782	Direct
Jul 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	15,884	$14.51	$230,431	Direct
Apr 11, 2025	MLYS Mineralys Therapeutics, Inc.	Sale(S)	15,319	$12.19	$186,803	Direct

1-25 of 28 transactions

About Congleton Jon

Congleton Jon (SEC CIK 0001644975) files insider reports with the SEC as Chief Executive Officer of Mineralys Therapeutics, Inc. (MLYS), Director of IMMUNIC, INC. (IMUX) and Director of Avalyn Pharma Inc. (AVLN).

Signal8 holds 19 ownership filings by Congleton Jon (1 Form 3, 18 Form 4), filed between Oct 15, 2024 and Oct 2, 2026. Those filings report 28 transactions, from Oct 11, 2024 to Sep 30, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Congleton Jon's filings is in RADNOR, PA.

Recent filings by Congleton Jon

Sep 30, 2026: Open-market sale of MLYS shares (Form 4, code S).
Jul 13, 2026: Open-market sale of MLYS shares (Form 4, code S).
Jul 5, 2026: Grant or award of IMUX derivative securities (Form 4, code A).
Jun 30, 2026: Open-market sales of MLYS shares (2 lines, Form 4, code S).
Jun 29, 2026: Grant or award of IMUX derivative securities (Form 4, code A).

Other insiders filing for Mineralys Therapeutics, Inc. (MLYS)

Peterson Kristine, Director
COATS LONNEL, Director
Slingsby Brian Taylor, Director
Warren Eric, Chief Commercial Officer
Karydas Daphne, Director
Ferguson James J. III, Chief Medical Officer

How to read Form 4 transaction codes